Risk for at least one adverse event per patient · schizophrenia
1 finding from 1 review
Mental state · schizophrenia
1 finding from 1 review
Global state ‐ number of participants with relapse/exacerbations of psychosis (separated time points) ‐ < 12 months · schizophrenia
It is very uncertain whether summary of findings table ‐ CBT without antipsychotics changes global state ‐ number of participants with relapse/exacerbations of… compared with antipsychotics (very low certainty).
1 finding from 1 review
Leaving the study early/ loss to · schizophrenia
It is very uncertain whether summary of findings table ‐ CBT without antipsychotics changes leaving the study early ‐ for any reason ‐ overall acceptability… compared with antipsychotics (very low certainty).
1 finding from 1 review
Level of functioning · schizophrenia
1 finding from 1 review
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Summary of findings: lamotrigine probably leads to higher 50% or greater reduction in seizure frequency (ITT analysis) compared with placebo (moderate certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
Summary of findings: lamotrigine showed no clear difference in treatment withdrawal compared with placebo (moderate certainty).
1 finding from 1 review
Ataxia · people with drug‐resistant focal epilepsy
Summary of findings: lamotrigine probably leads to higher ataxia compared with placebo (moderate certainty).
1 finding from 1 review
Dizziness · people with drug‐resistant focal epilepsy
Summary of findings: lamotrigine probably leads to higher dizziness compared with placebo (moderate certainty).
1 finding from 1 review
Fatigue · people with drug‐resistant focal epilepsy
Summary of findings: lamotrigine probably leads to lower fatigue compared with placebo (moderate certainty).
1 finding from 1 review
Nausea · people with drug‐resistant focal epilepsy
Summary of findings: lamotrigine probably leads to higher nausea compared with placebo (moderate certainty).
1 finding from 1 review
Diplopia · people with drug‐resistant focal epilepsy
Summary of findings: lamotrigine probably leads to higher diplopia compared with placebo (moderate certainty).
1 finding from 1 review
FEV1 (% predicted): mean change from baseline · adults and children with cystic fibrosis
1 finding from 1 review
FEF25–75: rate of decline in FEF25–75 · adults and children with cystic fibrosis
1 finding from 1 review
Time to first exacerbation requiring intravenous antibiotics · adults and children with cystic fibrosis
1 finding from 1 review
QoL · adults and children with cystic fibrosis
1 finding from 1 review
Mucus weight · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Annual rate of change in % predicted FEV1 All participants · adults and children with cystic fibrosis
It is very uncertain whether CCPT changes FEV1: annual decline in FEV1 % predicted compared with ACBT (very low certainty).
1 finding from 1 review
Annual rate of change in % predicted FVC Subgroup: Under 13 years of age · adults and children with cystic fibrosis
It is very uncertain whether CCPT changes FVC: annual decline in FVC % predicted compared with ACBT (very low certainty).
1 finding from 1 review
FEF25–75: annual decline in FEF25–75 % predicted · adults and children with cystic fibrosis
It is very uncertain whether CCPT changes FEF25–75: annual decline in FEF25–75 % predicted compared with ACBT (very low certainty).
1 finding from 1 review